Xenon (XENE)
NASDAQ:XENE
Want to see XENE full AI Analyst Report?
XENE Stock Chart & Stats
$59.70
-$0.78(-1.91%)
At close: 4:00 PM EST
$59.70
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$28.19 - $63.95
Previous CloseN/A
Volume41.45K
Average Volume (3M)1.84M
Market Cap
$5.34B
Enterprise Value$3.92B
Total Cash (Recent Filing)$548.89M
Total Debt (Recent Filing)$7.94M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 06, 2026EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding95,427,160
10 Day Avg. Volume857,505
30 Day Avg. Volume1,835,066
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue522.32
Enterprise Value/Gross Profit-55.33
Enterprise Value/Ebitda-10.90
Forecast
1Y Price Target
$77.48Price Target Upside29.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-4.79
Revenue Forecast (FY)$4.42M
Bulls Say, Bears Say
Bulls Say
Commercial Potential And AdoptionOnce‑daily dosing, no titration, and minimal drug‑drug interactions support broader use by general neurologists and underpin management's case for premium launch pricing.
EfficacyPhase 3 results showed larger-than-expected seizure reduction in a highly treatment‑resistant population, strengthening confidence in the drug's clinical effectiveness.
Mechanism And Pipeline ExpansionA novel Kv7 mechanism combined with supportive open‑label signals increases prospects for exploring additional central nervous system indications such as mood disorders.
Bears Say
Data Disclosure UncertaintyTopline communications omitted seizure‑freedom outcomes, creating uncertainty around a key clinical endpoint that influences physician prescribing decisions.
Regulatory And Indication RiskMaterial regulatory risk and a prior depression study failing its primary endpoint raise the possibility that clinical success in seizures may not translate to approval or label expansion.
Safety And TolerabilityNotable reports of dizziness and confusional states at higher doses could limit tolerability for some patients and constrain real‑world uptake.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $28.19 and its highest was $63.95 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $5.34B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Aug 06, 2026 which is in 89 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on May 07, 2026. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $0.009.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.13.
How many shares outstanding does Xenon have?
Xenon has 95,427,160 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went up 0.786%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.48 (29.78% Upside)
$77.48 (29.78% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 603.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.03%
12-Months-Change
Fundamentals
Return on Equity
-48.47%
Trailing 12-Months
Asset Growth
-8.01%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and corporate momentum: a highly favorable XTOL-2 Phase 3 data set with strong efficacy, long-term seizure freedom signals, a consistent safety profile, and a fortified balance sheet ($1.3B) supporting operations into 2029. The company has a clear regulatory path (NDA guidance for 2026) and active commercial and payer engagement. Remaining uncertainties are largely execution and timing risks (regulatory scheduling, commercial launch logistics, payer access) and limited near-term public granularity on Phase 1 pain data. On balance, the highlights are substantial and materially outweigh the modest operational and timing risks discussed.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$77.48
▲(29.78% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.11% Insiders
27.86% Mutual Funds
3.21% Other Institutional Investors
63.03% Public Companies and
Individual Investors